Evidence map›Paper›PMID 40596412›Full record

ArticleScientific reports2025

Development of a prognostic risk stratification model for HER2-positive breast cancer brain metastasis and its implications in guiding treatment decisions.

Jiaxin Chen, Yuan Sh, Danfeng Dong, Huicui Yan, Huiqiang Zhang, Zisheng Wu, Jinmei Zhou, Xuexue Wu, Fei Chu, Zefei Jiang and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Jiaxin Chen *Breast Cancer Department, The Fifth Medical Center of PLA General Hospital, Beijing, China.ORCID http://orcid.org/0000-0002-4616-0793
Yuan Sh *Fujian Provincial Key Laboratory of Brain Aging and Neurodegenerative Diseases, School of Basic Medical Sciences, Fujian Medical University, Fuzhou, 350108, Fujian Province, China.
Danfeng Dong *Department of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Huicui Yan *Department of Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China.
Huiqiang ZhangBreast Cancer Department, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Zisheng WuBreast Cancer Department, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Jinmei ZhouBreast Cancer Department, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Xuexue WuBreast Cancer Department, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Fei ChuElekta Instrument (Shanghai) Ltd, Beijing Branch, Beijing, China.
Zefei JiangBreast Cancer Department, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Shanhu LiDepartment of Genetic Engineering, Beijing Institute of Biotechnology, Beijing, China. lishanhu6@163.com.
Jin YangDepartment of Medical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. yangjin@mail.xjtu.edu.cn.
Ling XuDepartment of Thyroid and Breast Surgery, Peking University First Hospital, Beijing, China. Ling.XU@pkufh.com.
Tao WangBreast Cancer Department, The Fifth Medical Center of PLA General Hospital, The Second of Clinical Medicine, Southern Medical University, Anhui Medical University, Hefei, China. wangtao733073@163.com.ORCID http://orcid.org/0000-0002-2823-7937

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Brain metastasis occurs in approximately 50% of patients with advanced HER2-positive breast cancer. Despite improved prognosis, survival remains limited. This study aims to investigate the clinicopathological characteristics of HER2-positive breast cancer brain metastasis (BCBM) patients and their prognostic associations, to identify personalized treatment strategies to enhance survival. This retrospective study included HER2-positive BCBM patients treated at three institutions: the Fifth Medical Center of the Chinese PLA General Hospital, Peking University First Hospital, and the First Affiliated Hospital of Xi'an Jiaotong University. Clinical, pathological, and treatment data were collected. A prognostic model was developed using recursive variable selection, starting with significant variables from univariate analysis and refining them through a recursive loop in multivariate Cox regression. The model stratified patients into three risk groups: low-risk (score 0-1), intermediate-risk (score 2-3), and high-risk (score 4-6), based on various independent prognostic factors. The median survival times for the low-, intermediate-, and high-risk groups were 30, 20, and 10 months, respectively (P < 0.0001, HR

Indexed as

Brain NeoplasmsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesAdultAgedFemaleHumansMiddle AgedPrognosisRetrospective StudiesRisk AssessmentRisk FactorsROC CurveERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBrain metastasisBreast cancerHuman epidermal growth factor receptor 2-positivePrognostic model

Identifiers

PMID40596412
PMCPMC12215926

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.